IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome
Chang, Ying-Jun1,2; Zhao, Xiang-Yu1,2; Xu, Lan-Ping1,2; Liu, Dai-Hong1,2; Liu, Kai-Yan1,2; Chen, Yu-Hong1,2; Wang, Yu1,2; Zhang, Xiao-Hui1,2; Zhao, Xiao-Su1,2; Han, Wei1,2; Chen, Huan1,2; Wang, Feng-Rong1,2; Lv, Meng1,2; Huang, Xiao-Jun1,2,3
关键词Lymphocyte recovery unmanipulated haploidentical blood and marrow transplant absolute lymphocyte count immune recovery transplant outcomes myelodysplastic syndrome
刊名LEUKEMIA & LYMPHOMA
2013-12-01
DOI10.3109/10428194.2013.783912
54期:12页:2671-2677
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Hematology
研究领域[WOS]Oncology ; Hematology
关键词[WOS]STEM-CELL TRANSPLANTATION ; IMMUNE RECONSTITUTION ; HEMATOLOGIC MALIGNANCIES ; CLINICAL IMPACT ; CHRONIC GRAFT ; HOST-DISEASE ; CORD BLOOD ; T-CELLS ; HLA ; OUTCOMES
英文摘要

We investigated whether early lymphocyte recovery, after unmanipulated, haploidentical, blood and marrow transplant (HBMT), affected clinical outcomes in 78 patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia evolving from MDS. Lymphocyte recovery was based on the absolute lymphocyte count on day 30 (ALC-30). Patients with high ALC-30 (>= 300 cells/mL) had lower relapse rates (13.8% vs. 35.5%, p = 0.049) and lower incidence of bacterial infections (3.4% vs. 25.8%, p = 0.015) than those with low ALC-30 values. Multivariate analysis showed that a high ALC-30 was associated with improved overall survival (OS, hazard ratio [HR]: 0.099, 95% confidence interval [CI]: 0.029-0.337; p < 0.0001), improved leukemia-free survival (HR: 0.245, 95% CI: 0.112-0.539; p < 0.0001), lower relapse rate (HR: 0.096, 95% CI: 0.011-0.827; p = 0.033) and lower transplant-related mortality (TRM, HR: 0.073, 95% CI: 0.016-0.324; p = 0.001). Combinations of three mismatches in the human leukocyte antigen loci were associated with a higher TRM (HR: 5.026, 95% CI: 1.392-18.173; p = 0.014). Our results suggest that the ALC-30 can predict a favorable OS after unmanipulated HBMT.

语种英语
WOS记录号WOS:000326633700020
项目编号30725038
资助机构Clinical Subjects&prime ; Key Project of the Ministry of Health ; National Natural Science Foundation of China
引用统计
被引频次:8[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60125
专题北京大学第二临床医学院
医学人文研究院/公共教学部_哲学与社会科学系
北京大学第二临床医学院_血液科
作者单位1.Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China
2.Peking Univ, Inst Hematol, Beijing Key Lab HSCT, Beijing 100044, Peoples R China
3.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Chang, Ying-Jun,Zhao, Xiang-Yu,Xu, Lan-Ping,et al. Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome[J]. LEUKEMIA &amp; LYMPHOMA,2013,54(12):2671-2677.
APA Chang, Ying-Jun.,Zhao, Xiang-Yu.,Xu, Lan-Ping.,Liu, Dai-Hong.,Liu, Kai-Yan.,...&Huang, Xiao-Jun.(2013).Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome.LEUKEMIA & LYMPHOMA,54(12),2671-2677.
MLA Chang, Ying-Jun,et al."Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome".LEUKEMIA & LYMPHOMA 54.12(2013):2671-2677.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Chang, Ying-Jun]的文章
[Zhao, Xiang-Yu]的文章
[Xu, Lan-Ping]的文章
百度学术
百度学术中相似的文章
[Chang, Ying-Jun]的文章
[Zhao, Xiang-Yu]的文章
[Xu, Lan-Ping]的文章
必应学术
必应学术中相似的文章
[Chang, Ying-Jun]的文章
[Zhao, Xiang-Yu]的文章
[Xu, Lan-Ping]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。